Key Clinical Points Glycemic Control in Type 2 Diabetes Mellitus Intensive glycemic control
reduces the risk of microvascular complications of type 2 diabetes, but the effect of strict …

The management of hyperglycemia in patients with kidney failure is complex, and the goals
and methods regarding glycemic control in chronic kidney disease (CKD) are not clearly …

Background: The effects of sulfonylureas and metformin on outcomes of cardiovascular
disease (CVD) in type 2 diabetes are not well-characterized. Objective: To compare the …

Importance Preferred second-line medication for diabetes treatment after metformin failure
remains uncertain. Objective To compare time to acute myocardial infarction (AMI), stroke, or …

Abstract Aims In the EMPA‐REG OUTCOME® trial, the sodium‐glucose cotransporter 2
inhibitor empagliflozin when given in addition to standard care improved cardiovascular …

Background Metformin is recommended as a first-line treatment for patients with type 2
diabetes. However, use of this drug has been contraindicated in individuals with impaired …

Diabetic kidney disease (DKD) represents an enormous burden in patients with type 2
diabetes mellitus (T2DM). Preclinical studies using most glucose-lowering agents have …

Introduction: People with chronic kidney disease (CKD) of stages 3–5 (creatinine clearance<
60 ml/min) represent≈ 25% of patients with type 2 diabetes mellitus (T2DM), but the …

Purpose Several observational studies suggest that metformin reduces incidence cancer
risk; however, many of these studies suffer from time-related biases and several cancer …

Objectives To assess the distribution of antihyperglycemic treatments according to age and
renal function and its relationship with cardiovascular disease in type 2 diabetes mellitus …